Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

FDA Allows Third COVID-19 Vaccine Dose for Certain Immunocompromised People

Last updated on

The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer BioNTech COVID-19 vaccine (PDF) and the Moderna COVID-19 vaccine (PDF). The amendment allows for a third dose for certain immunocompromised people.

The third dose should be the same vaccine product as the initial two-dose mRNA COVID-19 vaccine series, Pfizer-BioNTech or Moderna. If the mRNA COVID-19 vaccine product given for the first two doses is not available, the other mRNA COVID-19 vaccine product may be administered.

A person should not receive more than three mRNA COVID-19 vaccine doses.

Check with your non-Medicare payor source to see if the third dose is covered. Medicare will pay for a third dose at the same rate as previous doses. This is about $40.

Read the FDA announcement.

Read the CDC’s interim clinical considerations for COVID-19 vaccines.